Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer - Trial NCT06403878
Access comprehensive clinical trial information for NCT06403878 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sichuan University and is currently Recruiting. The study focuses on Esophageal Cancer. Target enrollment is 68 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sichuan University
Timeline & Enrollment
Phase 2
May 01, 2024
Aug 01, 2026
Primary Outcome
Pathological complete response rate
Summary
We intend to conduct a prospective single-arm clinical study to explore the efficacy and
 safety of immunochemotherapy in neoadjuvant therapy in elderly patients with advanced
 esophageal squamous cell carcinoma. Most previous randomized controlled studies (such as the
 5010 study) have excluded older patients ≥70 years of age. However, in the real world,
 elderly patients with esophageal cancer account for a large number of patients, and elderly
 people have many complications and poor tolerance to treatment, which limits the application
 of synchronous chemoradiotherapy in this group. There is no standard treatment plan for
 patients over 70 years old, and the purpose of this study is to explore the effectiveness and
 safety of neoadjuvant immunochemotherapy in the treatment of this group of elderly people.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06403878
Non-Device Trial